https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-epithelial-ovarian-cancer-likelihood-of-approval/
Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer.
epithelial ovarian cancerdenileukin diftitoxpharmaceuticalslikelihood
https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-endometrial-cancer-likelihood-of-approval/
Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Endometrial Cancer.
denileukin diftitoxendometrial cancerpharmaceuticalslikelihood